01/25/2025
From Online: IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of IDEXX Cancer Dx™, a first-of-its-kind diagnostic panel with early detection of lymphoma in dogs, especially the 20 million dogs at higher risk* for cancer in North America.1 IDEXX Cancer Dx is an affordable and accessible blood test that can be added to panels for sick pets and integrated into annual wellness screenings for as low as $15, providing veterinarians in the U.S. with actionable results within 2–3 days.†
Cancer remains a leading cause of death in canines, with 1 in 4 dogs in the U.S. expected to be diagnosed with cancer in their lifetime.2 Lymphoma, one of the most common cancers in dogs, accounts for nearly a quarter of new cancer diagnoses.3 Treatment for canine lymphoma may help extend the lifespan and improve the quality of life for affected dogs, highlighting the critical need for early detection and intervention to improve outcomes. A recent survey indicates that 73% of pet owners are interested in having a cancer screening test for their pet,4signaling a strong demand for proactive, wellness-driven care. Early data shows IDEXX Cancer Dx testing can detect lymphoma before clinical signs are present, 5 supporting its utility in routine preventive care for at-risk dogs.
Read the entire article here: http://caninechronicle.com/?p=317170
